U.S., Feb. 15 -- ClinicalTrials.gov registry received information related to the study (NCT06826872) titled 'Efficacy and Safety of SPC1001 in Patients With Essential Hypertension' on Feb. 10.
Brief Summary: - Objective: This study aims to evaluate the safety and efficacy of the fixed-dose triple combination therapy (SPC1001) of candesartan, amlodipine, and indapamide in adult patients with essential hypertension compared to dual-component therapies of each ingredient for 8 weeks. Additionally, it seeks to confirm the contribution of each component at low doses.
- Inclusion Criteria: Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria.
- Exclusion Criteria: Patients whose bl...